A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants

CompletedOBSERVATIONAL

Enrollment

340

Participants

Timeline

Start Date

January 25, 2018

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions

Locally Advanced or Metastatic Breast Cancer

Interventions

DRUG

Eribulin mesylate

intravenous infusion

Trial Locations (14)

Eisai Trial site_03, Ansan

Eisai Trial site_04, Busan

Eisai Trial site_05, Busan

Eisai Trial site_06, Busan

Eisai Trial site_09, Daegu

Eisai Trial site_13, Daejeon

Eisai Trial site_14, Gwangju

Eisai Trial site_01, Seoul

Eisai Trial site_02, Seoul

Eisai Trial site_07, Seoul

Eisai Trial site_10, Seoul

Eisai Trial site_11, Seoul

Eisai Trial site_12, Seoul

Eisai Trial site_08, Suwon

All Listed Sponsors

lead

Eisai Korea Inc.

INDUSTRY

NCT03437083 - A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants | Biotech Hunter | Biotech Hunter